-
1
-
-
0142120646
-
Are all evidence-based practices alike? Problems in the ranking of evidence
-
Upshur, R. E. G., (2003) Are all evidence-based practices alike? Problems in the ranking of evidence. Canadian Medical Association Journal, 169 (7), 672-673.
-
(2003)
Canadian Medical Association Journal
, vol.169
, Issue.7
, pp. 672-673
-
-
Upshur, R.E.G.1
-
5
-
-
0032200198
-
Evidence-based medicine: A Kuhnian perspective of a transvestite non-theory
-
Couto, J. S., (1998) Evidence-based medicine: a Kuhnian perspective of a transvestite non-theory. Journal of Evaluation in Clinical Practice, 4 (4), 267-275.
-
(1998)
Journal of Evaluation in Clinical Practice
, vol.4
, Issue.4
, pp. 267-275
-
-
Couto, J.S.1
-
7
-
-
84866693521
-
-
Cartwright, N. Goldfinch, A. & Howick, J. (eds)Milan: Graduate Conference of the Graduate School in Social Sciences.
-
Cartwright, N., Goldfinch, A., &, Howick, J., (eds) (2007) Evidence-Based Policy: Where is Our Theory of Evidence? Milan: Graduate Conference of the Graduate School in Social Sciences.
-
(2007)
Evidence-Based Policy: Where Is Our Theory of Evidence?
-
-
-
9
-
-
0141558233
-
What evidence in evidence-based medicine?
-
Worrall, J., (2002) What evidence in evidence-based medicine? Philosophy of Science, 69 (Suppl.), S316-S330.
-
(2002)
Philosophy of Science
, vol.69
, Issue.SUPPL.
-
-
Worrall, J.1
-
10
-
-
0028923154
-
Grey zones of clinical practice: Some limits to evidence-based medicine
-
Naylor, C. D., (1995) Grey zones of clinical practice: some limits to evidence-based medicine. Lancet, 345, 840-842.
-
(1995)
Lancet
, vol.345
, pp. 840-842
-
-
Naylor, C.D.1
-
11
-
-
79951481957
-
Initial impact of the sequencing of the human genome
-
Lander, E. S., (2011) Initial impact of the sequencing of the human genome. Nature, 470, 187-197.
-
(2011)
Nature
, vol.470
, pp. 187-197
-
-
Lander, E.S.1
-
12
-
-
79952419254
-
Methodological and practical challenges for personalized cancer therapies
-
Wistuba, I. I., Gelovani, J. G., Jacoby, J. J., Davis, S. E., &, Herbst, R. S., (2012) Methodological and practical challenges for personalized cancer therapies. Nature Reviews Clinical Oncology, 8, 135-141.
-
(2012)
Nature Reviews Clinical Oncology
, vol.8
, pp. 135-141
-
-
Wistuba, I.I.1
Gelovani, J.G.2
Jacoby, J.J.3
Davis, S.E.4
Herbst, R.S.5
-
13
-
-
79952423736
-
Implications of personalized medicine - Perspective from a cancer center
-
Tursz, T., Andre, F., Lazar, V., Lacroix, L., &, Soria, J. C., (2011) Implications of personalized medicine-perspective from a cancer center. Nature Reviews. Clinical Oncology, 8 (3), 177-183.
-
(2011)
Nature Reviews. Clinical Oncology
, vol.8
, Issue.3
, pp. 177-183
-
-
Tursz, T.1
Andre, F.2
Lazar, V.3
Lacroix, L.4
Soria, J.C.5
-
14
-
-
84859839784
-
Personalized management of patients with solid cancers: Moving from patient characteristics to tumor biology
-
Awada, A., Vandone, A. M., &, Aftimos, P., (2012) Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Molecular Biology, 24, 297-304.
-
(2012)
Molecular Biology
, vol.24
, pp. 297-304
-
-
Awada, A.1
Vandone, A.M.2
Aftimos, P.3
-
15
-
-
84859377987
-
Role of randomized phase III trials in an era of effective targeted therapies
-
Sharma, M. R., &, Schilsky, R. L., (2012) Role of randomized phase III trials in an era of effective targeted therapies. Nature Reviews. Clinical Oncology, 9 (4), 208-214.
-
(2012)
Nature Reviews. Clinical Oncology
, vol.9
, Issue.4
, pp. 208-214
-
-
Sharma, M.R.1
Schilsky, R.L.2
-
16
-
-
0029912547
-
Why we need observational studies to evaluate the effectiveness of health care
-
Black, N., (1996) Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal, 312, 1215-1218.
-
(1996)
British Medical Journal
, vol.312
, pp. 1215-1218
-
-
Black, N.1
-
18
-
-
0027117969
-
Department of Health and Human Services. New drug, antibiotic, and biological drug product regulations; Accelerated approval-FDA. Final rule
-
Food and Drugs Administration (FDA).
-
Food and Drugs Administration (FDA) (1992) Department of Health and Human Services. New drug, antibiotic, and biological drug product regulations; accelerated approval-FDA. Final rule. Federal Register, 57, 58942-58960.
-
(1992)
Federal Register
, vol.57
, pp. 58942-58960
-
-
-
19
-
-
57849117384
-
New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)
-
Eisenhauer, E. A., Therasse, P., Bogaerts, J., et al,. (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). European Journal of Cancer, 45 (2), 228-247.
-
(2009)
European Journal of Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
20
-
-
84858396530
-
Redefining clinical trials: The age of personalized medicine
-
Vaidyanathan, G., (2012) Redefining clinical trials: the age of personalized medicine. Cell, 148, 2011-2012.
-
(2012)
Cell
, vol.148
, pp. 2011-2012
-
-
Vaidyanathan, G.1
-
21
-
-
84860443404
-
Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design
-
Verweij, J., de Jonge, M., Eskens, F., &, Sleijfer, S., (2012) Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. Molecular Oncology, 6 (2), 196-203.
-
(2012)
Molecular Oncology
, vol.6
, Issue.2
, pp. 196-203
-
-
Verweij, J.1
De Jonge, M.2
Eskens, F.3
Sleijfer, S.4
-
22
-
-
84859438079
-
Hurdles in anticancer drug development from a regulatory perspective
-
Jonsson, B., &, Bergh, J., (2012) Hurdles in anticancer drug development from a regulatory perspective. Nature Reviews. Clinical Oncology, 9 (4), 236-243.
-
(2012)
Nature Reviews. Clinical Oncology
, vol.9
, Issue.4
, pp. 236-243
-
-
Jonsson, B.1
Bergh, J.2
-
24
-
-
84859441677
-
Drug development and clinical trials - The path to an approved cancer drug
-
Rubin, E. H., &, Gilliland, D. G., (2012) Drug development and clinical trials-the path to an approved cancer drug. Nature Reviews. Clinical Oncology, 9 (4), 215-222.
-
(2012)
Nature Reviews. Clinical Oncology
, vol.9
, Issue.4
, pp. 215-222
-
-
Rubin, E.H.1
Gilliland, D.G.2
-
25
-
-
79952267810
-
Traditional drug-discovery model ripe for reform
-
Cressey, D., (2011) Traditional drug-discovery model ripe for reform. Nature, 471, 17-18.
-
(2011)
Nature
, vol.471
, pp. 17-18
-
-
Cressey, D.1
-
26
-
-
84866713197
-
Studies in history and philosophy of biological and biomedical sciences
-
Craver, C. F. & Darden, L. (eds).
-
Craver, C. F., &, Darden, L., (eds) (2005) Studies in history and philosophy of biological and biomedical sciences. Special Issue: Mechanisms in Biology, 31 (2).
-
(2005)
Special Issue: Mechanisms in Biology
, vol.31
, pp. 2
-
-
-
27
-
-
0024502741
-
Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of the data from 157 cases
-
Bayes de Luna, A., Coumel, P., &, Leclercq, J. F., (1989) Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of the data from 157 cases. American Hearth Journal, 117, 151-159.
-
(1989)
American Hearth Journal
, vol.117
, pp. 151-159
-
-
Bayes De Luna, A.1
Coumel, P.2
Leclercq, J.F.3
-
28
-
-
0035891624
-
Sudden death due to cardiac arrhythmias
-
Huikuri, H. V., Castellanos, A., &, Meyburg, R. J., (2001) Sudden death due to cardiac arrhythmias. New England Journal of Medicine, 345, 1473-1482.
-
(2001)
New England Journal of Medicine
, vol.345
, pp. 1473-1482
-
-
Huikuri, H.V.1
Castellanos, A.2
Meyburg, R.J.3
|